MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Stefan Schreiber  ¹     David T. Rubin  ²     Hon Ho Yu  ³     Irene Modesto  ⁴     Xiang Guo  ⁵     Chinyu Su  ⁵     Kenneth Kwok  ⁵     Hyejin Jo  ⁵     Yan Chen  ⁵     Arne Yndestad  ⁶     Walter Reinisch  ⁷     Marla C. Dubinsky  ^8    
1 University Hospital Schleswig-Holstein, Kiel, Germany
² University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, United States
³ LKS Institute of Health Science, Chinese University of Hong Kong, Hong Kong, China
⁴ Pfizer Inc, New York, United States
⁵ Pfizer Inc, Collegeville, United States
⁶ Pfizer Inc, Oslo, Norway
⁷ Medical University of Vienna, Vienna, Austria
⁸ Icahn School of Medicine at Mount Sinai, New York, United States

Session
Safety and emergencies in lower GI disease (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)